Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thorough QT/QTc trial of RPC 1063 in volunteers.

Trial Profile

Thorough QT/QTc trial of RPC 1063 in volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis; Ulcerative colitis
  • Focus Adverse reactions
  • Acronyms TQT
  • Most Recent Events

    • 28 Oct 2017 Results of analysis assessing cardiac safety of ozanimod in RADIANCE and QT/QTc trials (see CTP 239937) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 24 Dec 2013 New trial record
    • 05 Jun 2013 Primary endpoint `No significant difference between RPC 1063 and placebo in prolongation of corrected QT interval' has been met, according to a Receptos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top